VITAMIN RESEARCH PRODUCTS – Trademark Portfolio
Entity Type: 03
VITAMIN RESEARCH PRODUCTS holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include AGEBLOCK. The owner is based in Carson City, NV.
4610 Arrowhead Drive
Carson City, NV 89706
Showing of trademarks Trademarks
Trademark Classifications
VITAMIN RESEARCH PRODUCTS's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Frequently Asked Questions
How many trademarks does VITAMIN RESEARCH PRODUCTS have?
VITAMIN RESEARCH PRODUCTS has 11 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned, 7 cancelled.
What trademark classes does VITAMIN RESEARCH PRODUCTS file in?
VITAMIN RESEARCH PRODUCTS files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 30 (Staple Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are VITAMIN RESEARCH PRODUCTS's most well-known trademarks?
VITAMIN RESEARCH PRODUCTS's registered trademark portfolio includes well-known marks such as AGEBLOCK. These are among 1 currently registered trademark in the portfolio.
What is VITAMIN RESEARCH PRODUCTS's trademark registration success rate?
VITAMIN RESEARCH PRODUCTS has a 9% trademark registration rate, with 1 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.